A Phase Ib Clinical Trial to Evaluate the Administration of Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer
Latest Information Update: 03 Jan 2025
At a glance
- Drugs SLATE 001 (Primary) ; TCR-transduced lymphocytes (Primary) ; Aldesleukin; Cyclophosphamide; Fludarabine; Mesna
- Indications Advanced breast cancer; Colorectal cancer; Gastrointestinal cancer; Non-small cell lung cancer; Ovarian cancer; Solid tumours; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 17 May 2024 Planned initiation date (estimated date of first participant enrollment) changed to 23 May 2024.
- 25 Apr 2024 Planned initiation date changed from 30 Apr 2024 to 1 May 2024.
- 24 Apr 2024 Planned initiation date (estimated date of first participant enrollment) changed to 30 Apr 2024.